Hualan Biological Engineering Inc. (002007.SZ)

CNY 17.38

(-0.46%)

Market Cap (In CNY)

31.29 Billion

Revenue (In CNY)

5.34 Billion

Net Income (In CNY)

1.48 Billion

Avg. Volume

14.58 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
13.72-22.3
PE
23.21
EPS
0.73
Beta Value
0.344
ISIN
CNE000001JN8
CUSIP
-
CIK
-
Shares
1876321220.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Bei Fan
Employee Count
-
Website
https://www.hualanbio.com
Ipo Date
2004-06-25
Details
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.